Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $88.55M |
| Gross Profit (TTM) | $66.84M |
| EBITDA | $-51.02M |
| Operating Margin | -62.90% |
| Return on Equity | -86.20% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $2.15 |
| Book Value | $1.09 |
| Price-to-Book | 1.24 |
| Price-to-Sales (TTM) | 0.63 |
| EV/Revenue | 0.582 |
| EV/EBITDA | -5.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -8.70% |
| Shares Outstanding | $42.24M |
| Float | $37.09M |
| % Insiders | 4.66% |
| % Institutions | 81.92% |
Volatility is currently contracting